Pharma major Dr Reddy’s Laboratories has launched Ropinirole Hydrochloride XR (Extended-Release) tablets in the US market.
The tablets are a bioequivalent generic version of Requip XL tablets of SmithKline Beecham Ltd which are indicated for the treatment of Parkinson’s disease.
The Requip XL brand had US sales of approximately $58 million for the most recent twelve months ending March 2012, according to IMS Health, the company said in a release on Thursday.